The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients (CROSBI ID 91529)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Topić, Elizabeta ; Štefanović, Mario ; Ivanišević, Ana-Maria ; Petrinović, Rajka ; Čurčić, Ivica
engleski
The cytochrome P450 2D6 (CYP2D6) gene polymorphism among breast and head and neck cancer patients
The prevalence of CYP2D6*3 and CYP2D6*4 alleles in normal controls and cancer patients was studied using the reliable PCR-SSCP method. In control group (n=144), four subjects (2.8%) were found to carry CYP2D6*3 allele (heterozygote), while 30 (20.8%) subjects carried CYP2D6*4 allele (18.8% heterozygotes, 2.1% homozygotes). One (1.3%) of the breast cancer (BC) patients (n=76) carried CYP2D6*3 allele, but 24 (31.6%) carried CYP2D6*4 allele (26.3% heterozygotes, 5.3% homozygotes). In head and neck cancer (HNC) group (n=56), two (3.6%) patients were heterozygous for CYP2D6*3 mutation and 15 (26.8%) for CYP2D6*4 mutation. 14/56 (25%) and 1/56 (1.8%) of these patients carried heterogygous and homozygous mutation, respectively. In controls, 2.1% were identified as poor metabolizers, 76.4% as extensive metabolizers, and 21.5% as intermediate heterozygotes. In BC group, 5.3%, 27.6% and 67.1% were classified as PM, IEM, and EM respectively. In HNC group, the incidence of PM was 1.8, but as many as 28.6 % were identified as IEM phenotypes.
CYP2D6 polymorphism; PCR-SSCP; breast cancer; head and neck cancer
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano